Abvc biopharma announces reverse stock split

Fremont, ca, july 24, 2023 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced a reverse stock split of its common stock ("reverse stock split") of one post-split share for every ten pre-split shares in an effort to regain compliance with nasdaq's listing rules. the company expects the reverse stock split to be effective as of 12:01 a.m. est on july 25, 2023, authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock under the new cusip number: 00091f 304.
ABVC Ratings Summary
ABVC Quant Ranking